Below you will find the latest news from AbSorber. For further information please contact Anders Karlsson (anders.karlsson@absorber.se), AbSorber.
Clinical use of XM-ONE® was highlighted at a symposium at the annual American Society of Histocompatibility and Immunogetetics (ASHI) meeting in New Orleans
New study confirms that XM-ONE® identifies kidney transplant recipients at increased risk for acute rejection.
AbSorber to host a Scientific Symposium at the American Transplant Congress in Philadelphia, PA
AbSorber and Olerup SSP has signed an exclusive distribution agreement for the Brazilian market, the world's second largest transplantation market after the US. Partner in Brazil is Genese Produtos Diagnosticos Ltda in Sao Paulo.
AbSorber has submitted a 510K to the FDA (U.S. Food and Drug Administration) for a new version of the Company’s transplantation crossmatch, XM-ONE®. This new version has the potential to replace current flow Cytometry based crossmatch tests.
AbSorber hosted a morning symposium at The Transplantation Society’s 13th International Congress in Vancouver, Canada.
Improving outcomes in kidney transplantation: Non-HLA antibodies and Enhanced Clinical Risk Assessment
At the American Transplant Congress in San Diego the organizers held a workshop of the subject of Endothelial Cell Crossmatch.
AbSorber strengthen its position on the important US market by acquiring NorDiag’s share of Olerup Inc. AbSorber buys the company together with SSP Primers and after the transition will AbSorber own 50 percent of Olerup Inc. and SSP Primers 50 percent.
AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product.
New global distribution partner effective from July 1, 2009. The new distributor, Olerup International, gives AbSorber the opportunity to sell XM-ONE® and future products globally with a highly specialized sales force within the Transplantation segment.
Ron Shapiro, Professor of surgery at the Thomas E. Starzl Institute of University of Pittsburgh Medical Center discusses the recently published multicenter study of Absorbers’ endothelial crossmatch, XM-ONE, at a video blog at Medscape.com.
AbSorber’s transplantation crossmatch test XM-ONE® was evaluated in a large clinical study and the results are now published in the prestigious international medical journal Transplantation.
AbSorber will kick-off the U.S. launch of its transplantation crossmatch test XM-ONE® at the ASHI annual meeting in Toronto. XM-ONE® received FDA registration in August 2008.
AbSorber has received patent protection for the transplantation crossmatch test XM-ONE® in New Zealand. New Zealand is thereby the first country to approve a patent for AbSorber’s product.
The Swedish biotech company AbSorber recently received FDA approval in the U.S. for its patented transplantation test XM-ONE®. Now AbSorber has received further support for its transplantation test from a major clinical trial in which six well-reputed...
The Swedish biotech company AbSorber has been given clearance by the U.S. Food and Drug Administration (FDA) to market and sell its XM-ONE® transplantation test in the U.S. Initially, sales of XM-ONE® in the U.S. will target the kidney transplantation...
Anders Karlsson has been appointed the new CEO of the transplantation company AbSorber. Karlsson has been COO of the company since the fall. AbSorber’s former CEO Ingemar Lagerlöf is taking on the role of member of the board of AbSorber.
LinkMed’s portfolio company AbSorber has been granted a patent in the U.S. for an AB0 column that the company is developing to facilitate transplantations between individuals of different blood groups.
AbSorber is pleased to announce the appointment of Anders Karlsson as Chief Operating Officer (COO). Karlsson joins AbSorber from Novartis, where he was CEO for the company’s operations in Norway.
AbSorber AB, launched its first product, XM-ONE, at the end of 2006. AbSorber’s next product – an AB0 diagnostic test – was presented at a conference on AB0 incompatible transplantation outside Stockholm.
AbSorber AB has appointed Camilla Tell Järte as Medical/Marketing Manager. In this capacity, Camilla will mainly be engaged in the marketing of XM-ONE. She will also play an important role in the planning process for AbSorbers coming product portfolio.
The Swedish biotech company AbSorber has entered into an agreement with BD (Becton, Dickinson and Company) regarding XM-ONE, AbSorber’s novel CE-marked transplantation cross match test kit.